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 INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoim-
mune disease with broad clinical manifestations char-
acterized by the production of autoantibodies1 which 
can have multi -organ involvement2 with tissue damage 
produced mainly by complement activation by immune 
complexes (IC).3 As a result of this activation, patients 
present hypocomplementaemia during disease flares, 
but C3 and C4 levels are expected to return to normal 
range between flares. Complement alternative pathway 
activation with C3 deficiency has been reported in SLE 
manifestations, notably lupus nephritis.4,5 However, this 
association is unclear, as partial deficiencies of comple-
ment proteins have not been associated with SLE.6,7 
Inherited deficiencies of several complement proteins 
strongly predispose to SLE while mutations of comple-
ment inhibitors are found mostly in kidney diseases such 
as atypical haemolytic uraemic syndrome (aHUS).
Herein we present a very challenging case of severe 
SLE with multisystem involvement with C3 levels per-
sistently below normal range and mutations of com-
plement regulators of the alternative pathway, raising 
further considerations regarding treatment approach.
 ABSTRACT
Systemic lupus erythematosus (SLE) is an autoimmune disease which can involve almost any organ, making 
its difficult therapeutic approach. Immune complex deposition can often activate complement, accounting for 
many of SLE clinical manifestations and laboratory findings.
We present a case of a patient who presented with acute pancreatitis and acute kidney injury as onset mani-
festations of SLE, later developing neurological manifestations, who was successfully treated with rituximab, 
plasma exchange and steroids as induction therapy. Persistently low C3 level led to a genetic analysis of the 
complement system components. We found three polymorphisms in the alternative pathway of complement 
regulators (complement factor H c2669 G>T, p.Ser890Ile and c3019 G>T, p.Val1007Leu and complement factor I 
c.482+6 G>T), two of which have been correlated with atypical haemolytic uraemic syndrome and dense deposit 
disease and also complement factor H -related protein (CFHR1 and CFHR3) mutations by deletion. This raises the 
question whether these polymorphisms and mutations played any role in our patient’s clinical course.
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 CASE REPORT
An African -native 45 -year -old woman was admitted 
to the emergency department with dyspnoea, fever 
(38.0°C), headache, abdominal pain and diarrhoea over 
the course of the previous two days. She also com-
plained of sore throat, foamy urine and low urine out-
put over the last few days. She reported complaints of 
low -grade fever (37.5 ± 37.8°C), malaise, anorexia dur-
ing the previous month and weight loss of approxi-
mately 35kg in the last two months. She had been 
previously medicated with non -steroidal anti-
-inflammatory drugs and amoxicillin -clavulanic acid.On 
observation, she was sleepy (GCS 12), hypotensive (BP 
86/42mmHg, HR 102ppm), with red throat and diffuse 
abdominal pain. Laboratory study revealed haemoglo-
bin 7.9g/dL, WBC 5.6x10/L, platelet count 109x10/L, 
AST 89UI/L, ALT 34UI/L, ALP 261UI/L, GGT 405UI/L, 
LDH 517UI/L, total bilirubin 0.29mg/dL), serum amylase 
3096 UI/L, serum albumin 1.13g/dL, serum creatinine 
(sCr) 6.17mg/dL, urea 116mg/dL, triglycerides 515mg/
dL, total cholesterol 179mg/dL and raised inflammatory 
markers: CRP 6.96mg/dL, ESR 140mm. Her urine 
showed haematuria and proteinuria (Hb 2+, Prot 
>400mg/dL, albumin -creatinine ratio in urine (ACR) 
7300mg/g). An abdominal CT was performed and con-
firmed acute pancreatitis (Figure 1).
Immunology studies showed antinuclear antibodies 
1/320, raised anti -dsDNA antibodies 78 UI/mL, positive 
anti -RPN, and extremely low C3 and C4 complement 
fraction (41, 6.4 mg/dL respectively). We ruled out 
thrombotic microangiopathy since she had normal 
haptoglobin level (131mg/dL) and the peripheral blood 
smear did not show any schizocytes. Also, serology for 
HIV, Hepatitis B and C, Epstein -Barr Virus, CMV and 
syphilis, blood and urine cultures and search for Myco-
bacterium tuberculosis and Plasmodium falciparum 
were all negative.
The diagnosis of SLE was therefore established with 
severe renal, haematological and pancreatic involvement.
The patient rapidly developed thrombocytopaenic 
anaemia, oligoanuria and tetraparesis with nystagmus 
and opsoclonus. Brain MRI showed hyperintense signal 
(long TR and T2) on the right side of the brainstem and 
medium cerebellar stalk. EMG showed predominantly 
motor polyneuropathy. Renal replacement therapy was 
started together with intravenous methylprednisolone 
500mg pulses (3 days) followed by oral prednisolone 
(PDN 60mg od). As haematological and neurological 
disorders progressed, with very low platelet count 
(21000/uL), weekly rituximab (RTX) was started 
(375mg/m2 of body surface area) on a total of 4 doses. 
One day later (at 9th day of admission) plasma exchange 
(PE) was started, undergoing 5 PE treatments.
Kidney function rapidly improved, stopping haemo-
dialysis at the 5th day after RTX treatment. Haemato-
logical, neurological and pancreatic improvement was 
evident after PE (3rd week of entire treatment).
Figure 1
Contrast enhanced CT: peripancreatic liquid collections. The pancreas 
captures contrast in homogenous patter with global increase in its 
dimensions.
 
Figure 2
Kidney biopsy: light microscopy, silver stain 20x – focal membrane 
reaction with double countor. 
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Kidney biopsy was performed on the 30th day of 
admission and showed an active, diffuse, global, pro-
liferative glomerulonephritis classified as class IV -G 
Lupus Nephritis (ISN/RPS 2004 classification) with activ-
ity index of 4/24 and chronicity index of 1/12 (Figure 
2). Immunofluorescence (IF) showed granular mesan-
gial and pseudolinear membranous deposits of IgG 
(+++), C3 (+++), C1 (+++), IgA (++) and IgM (+) (Figure 
3) and electron microscopy (EM) showed electron 
dense subendothelial immune deposits, resembling 
dense deposit disease (DDD) (Figure 4).
Mycophenolate mofetil (MMF) was started on the 
31st day of admission (1000mg bid), tapering PDN to 
30mg od at discharge, two months after admission.
Laboratory findings at discharge were Hb 9.5g/dL, 
platelet count 371x10/L, sCr 1.10mg/dL, ACR 910mg/g, 
normal C3 and C4 (93, 14.3mg/dL) and negative dsDNA 
(9.7UI/mL).
During follow -up, C3 levels have remained below 
the normal range, despite there being no signs of SLE 
flare. Therefore, complement molecular study was per-
formed in an attempt to identify abnormalities in the 
alternative complement pathway. Genetic analysis 
revealed that the patient carried two mutations in het-
erozygosis of complement factor H (CFH) gene (c2669 
G>T, p.Ser890Ile and c3019 G>T, p.Val1007Leu) and 1 
mutation in heterozygosis of Factor I (CFI) gene (c.482+6 
G>T). Also, mutations by deletions on complement 
factor H -related proteins (CFHR), CFHR1 and CFHR3 in 
heterozygosis.
At 30 month follow -up patient complains only of 
peripheral polyneuropathy, remaining in total remission 
with creatinine clearance of 129.9mL/min, proteinuria 
of 0.814g/day, and ACR 206mg/g, with normal urine 
sediment, with no haematological abnormalities or 
autoantibodies. Treatment remained based on MMF 
and hydroxychloroquine until two years of follow -up.
 DISCUSSION
The patient presented here had a severe multiorgan 
presentation of SLE with gastrointestinal, renal, hae-
matological and neurological involvement. Acute pan-
creatitis is a rare manifestation of SLE.8 -13 Pathophysiol-
ogy is unclear but available evidence suggests that 
vasculitis, microthrombus formation, anti -pancreatic 
antibodies and inflammation due to T -cell infiltration 
and complement activation might be involved.13 Neu-
ropsychiatric systemic lupus erythematosus (NPSLE) is 
the least understood but probably the most prevalent 
manifestation of lupus. Its pathogenesis is multifactorial 
and involves various inflammatory cytokines, autoan-
tibodies, and ICs resulting in vasculopathic, cytotoxic 
and autoantibody -mediated neuronal injury and is 
associated with increased morbidity and mortality.14 
Our patient presented with light neurological changes 
Figure 3
Kidney biopsy: immunofluorescence to C1 20x – diffuse granular 
deposition of C1.
 
Figure 4
Kidney biopsy: electron microscopy 4000x – diffuse subendothelial 
deposits.
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but developing rapidly severe brainstem involvement, 
nystagmus and cognitive impairment. Haematological 
abnormalities are common findings in patients with 
SLE. Low platelet count is mainly associated to neu-
ropsychiatric manifestation, haemolytic anaemia, and 
kidney disease.15 Thrombocytopenia can be regarded 
as an important prognostic indicator of survival in 
patients with SLE. Our patient presented with severe 
thrombocytopaenia and severe anaemia, but no signal 
of haemolysis was found. Additionally, the patient 
developed severe acute kidney injury due to class IV -G 
lupus nephritis with full house immune deposits, but 
with C3 (+++), no C4 on IF and EM showing electron-
-dense deposits resembling DDD pattern. As serum C3 
level persisted low, the patient was genetically studied 
demonstrating 2 CFH and 1 CFI mutations, associated 
with deletion on CFHR1 and CFHR3. Complement fac-
tors consumption during SLE flares exacerbations is a 
hallmark of this syndrome. In fact, low C3 and C4 and 
a high dsDNA titre can preclude renal flare.16 CFH is 
the main regulator of the alternative pathway of the 
complement system and regulates complement activa-
tion both in fluid phase and on cellular surfaces.17 
Mutations and polymorphisms in CFH gene have been 
found to be associated with aHUS, DDD and age -related 
macular degeneration. The two mutations identified 
in our patient in CFH have been repeatedly reported 
to be associated with aHUS, but have also been found 
in the other two conditions.18,19
Many of these CFH genetic variations disrupt the 
regulatory role of factor H. However, data illustrate that 
these amino acid substitutions in those mutations do 
not influence the expression/secretion of FH.20 Notwith-
standing, the same authors concluded that associations 
of complement regulation abnormalities could explain 
the persistent complement alternative pathway activa-
tion. Our patient has a CFI mutation with unknown effect 
to our knowledge, and moreover she also carries CFHR1 
and CFHR3 deletion. It was described that these muta-
tions encode a CFH protein with reduced capacity to 
regulate the activity on cellular surfaces being associated 
with an increased risk of aHUS.19 The latter observation 
emphasizes that multiple concurrent factors may be 
necessary in individual patients for alternative pathway 
disease manifestation. A recently published study 
showed that CFH deficiency accelerates development 
of lupus nephritis in an accurate mouse model of human 
SLE (MRL -lpr mice), sharing many features of SLE in terms 
of production of autoantibodies and consumptive hypoc-
omplementemia.21 Pathologic findings in these animals 
included marked glomerular subendothelial, mesangial 
and subepithelial deposition of IC containing C3.
It is remarkable that a SLE patient with severe sys-
temic involvement, particularly severe lupus nephritis 
with C3 deposition similar to that of DDD, also carried 
all these genetic mutations, raising the question wheth-
er they may play any role in our patient’s clinical pres-
entation. However, it is also known that there is a high 
allelic frequency of these two CFH variants in sub-
-Saharan African populations20, supporting the hypoth-
esis of this being an incidental finding.
Our patient showed a good response to PE associ-
ated with RTX and steroids as induction treatment. 
Although randomized controlled trials (RCTs) have 
failed to show superiority of rituximab over standard 
immunosuppression alone, in reducing clinical activ-
ity and achieving complete or partial remission with-
out subsequent flares22,23, data from one of these 
trials (LUNAR) showed a statistical significant differ-
ence in the number of patients reaching proteinuria 
remission at 78 -weeks.24,25 Moreover, these two tri-
als excluded patients with severe or refractory SLE, 
such as the case presented, with severe gastrointes-
tinal, neurological, haematological and renal involve-
ment, which might be a reason to consider this thera-
peutic option. Regarding patients with SLE with 
NPSLE, a recent review of published data of patients 
treated with RTX found an 85% response rate with 
partial or complete remission.26 Regarding PE there 
is lack of evidence in lupus nephritis treatment. How-
ever, the American Society for Apheresis accepts it 
as second -line therapy to treat SLE manifestations, 
such as NPSLE.27 It has been proposed that PE modu-
lates humoral components of immune response, 
removing autoantibodies and IC. Despite no RCTs 
showing its efficacy in SLE patients, there has been 
case series published showing evidence of its utility, 
mainly in NPSLE, simultaneously with other immu-
nosuppressive treatment.28
In summary, we report a severe SLE case with acute 
pancreatitis, NPSLE, severe bicytopenia and lupus 
nephritis, who carries different complement alternative 
pathway mutations. To our knowledge, this is the first 
case published with this association. The specific role 
of these findings is not yet clarified. Nevertheless, we 
achieved a complete prolonged remission with treat-
ment with RTX, PE and steroids as induction treatment 
and MMF as maintenance therapy. Early diagnosis and 
treatment probably played a major role in the favour-
able outcome of this serious and rapidly deteriorating 
SLE case.
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